Earnings Roundup: Specialty/Smaller Biopharmas See Modest Hit From Pandemic
First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.
You may also be interested in...
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.